LYNPARZA® (olaparib) Approved by US FDA in Germline BRCA-Mutated Metastatic Breast Cancer

12:45 EST 12 Jan 2018 | Businesswire

This article has expired, however you can still download the PDF.
LYNPARZA is the first and only PARP inhibitor approved for use beyond ovarian cancer LYNPARZA reduced the risk of disease progression or death by 42% compared to standard of care chemotherapy AstraZeneca and ...

Other Sources for this Article

Michele Meixell, +1 302 885 2677
Stephanie Wiswall, +1 302 885 2677


More From BioPortfolio on "LYNPARZA® (olaparib) Approved by US FDA in Germline BRCA-Mutated Metastatic Breast Cancer"

Quick Search


Relevant Topics

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...

AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...